Research programme: enzyme therapeutics - Aeglea Biotherapeutics

Drug Profile

Research programme: enzyme therapeutics - Aeglea Biotherapeutics

Alternative Names: AEB 2109; AEB 3103; AEB 4104; AECase/AEB3103; AEMase/AEB2109

Latest Information Update: 30 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aeglea Biotherapeutics
  • Class Antineoplastics; Enzymes
  • Mechanism of Action Enzyme replacements; Neutral amino acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Homocystinuria; Solid tumours

Most Recent Events

  • 03 May 2017 Aeglea Biotherapeutics announces intention to submit IND to US FDA for Solid tumours, Homocystinuria and Haematological malignancies in 2018
  • 21 Nov 2016 Pharmacodynamics data from a preclinical trial for AEB 3103 in Solid tumours and Haematological malignancies released by Aeglea Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top